Eli Lilly (LLY) announced that Foundayo is now available to adults with obesity or overweight with weight-related medical problems following the FDA approval on April 1. Foundayo is a once-daily pill for weight loss that can be taken without food or water restrictions. People can now access Foundayo via LillyDirect and telehealth providers, with availability expanding to U.S. retail pharmacies beginning today. Foundayo is available starting at $149 per month at the lowest dose for self-pay patients. Eligible and commercially insured people with coverage for Foundayo may pay as little as $25 per month with the Foundayo savings card. Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning July 1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) CEO Says Company Ready to Scale Production of Weight-Loss Pill
- Leerink calls AC Immune- Eli Lilly Tau amendment ‘great news’
- Novo Nordisk Stock (NVO) Slips despite Milestone in Obesity Race with Eli Lilly
- Lexaria Bioscience ‘applauds’ Eli Lilly’s Foundayo drug approval
- AI Models Diverge on Eli Lilly: Premium Growth or Priced for Perfection?
